Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Regular-Growth
The fund is rated 1 star. Taken together, the fund's movement relative to its index and annual fee of 1.1% place it behind most similar funds.
This index fund/ETF has a beta of 0.664%, and an expense ratio of 1.1%, giving it a 1.0 star rating, based on the principle that lower values of |1-beta| and expense ratio result in higher ratings.
Our score weighs long-term performance, risk and consistency — not just past returns.
Returns
As of 7 Oct 2026
Risk ratios
As of 30 Sep 2026
Portfolio
As of 31 Aug 2026
Market-cap split
Sector allocation
Holdings (45)
| Holding | % of fund | Value | Shares |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 10.99% | ₹21.94 Cr | 1,10,519 |
| Divi's Laboratories Ltd. | 6.96% | ₹13.89 Cr | 14,674 |
| Eli Lilly And Co | 6.34% | ₹12.66 Cr | 1,147 |
| Apollo Hospitals Enterprise Ltd. | 5.51% | ₹11 Cr | 12,363 |
| Max Healthcare Institute Ltd. | 4.52% | ₹9.03 Cr | 86,669 |
| Torrent Pharmaceuticals Ltd. | 4.45% | ₹8.88 Cr | 17,520 |
| Cipla Ltd. | 4.38% | ₹8.74 Cr | 62,015 |
| Johnson & Johnson Ltd. | 4.37% | ₹8.73 Cr | 3,439 |
| Laurus Labs Ltd. | 4.14% | ₹8.25 Cr | 43,104 |
| Dr. Reddy's Laboratories Ltd. | 3.56% | ₹7.1 Cr | 61,513 |
Fund details
Long Term Capital appreciation. Passive investment in equity and equity related securities replicating the composition of MSCI India Domestic & World Healthcare 45 Index, subject to tracking error.
The scheme seeks to invest in stocks comprising of the MSCI India Domestic & World Healthcare 45 Index with the objective to provide investment returns that, before expenses, closely corresponds to the returns equivalent to the index, subject to tracking errors.